Showing results (131-140 of 1,877) with videos related to
Sort By:
Pageof 188
Immunotherapy|June 30, 2021
PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmareJoseph Zouein, Carole Kesrouani, Hampig Raphael KourieImmunotherapy|July 7, 2021
Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical applicationGang Xiao, Zhiyuan Liu, Xuan Gao, et al.Immunotherapy|May 11, 2022
A review of the totality of evidence in the development of ABP 798, a rituximab biosimilarPatrick Cobb, Dietger Niederwieser, Stanley Cohen, et al.Immunotherapy|July 14, 2021
Durable complete remission of leptomeningeal melanoma by intrathecal methotrexate maintained with systemic ipilimumabCarmen Dietrich, Martin Salzmann, Andreas Steinbrecher, et al.Immunotherapy|November 30, 2017
PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanomaAsad Javed, David Arguello, Curtis Johnston, et al.Immunotherapy|April 13, 2021
Capillary-leak syndrome: an unrecognized early immune adverse effect of checkpoint-inhibitors treatmentRuth Percik, Asher Nethanel, Yair LielImmunotherapy|June 14, 2019
Impact of synchronized anti-PD-1 with Ad-CEA vaccination on inhibition of colon cancer growthYuanyuan Sun, Suya Wang, Hainan Yang, et al.Immunotherapy|October 15, 2019
Dendritic cell-based vaccine targeting aspartate-β-hydroxylas represents a promising therapeutic strategy for HCCYujiao Zhou, Chengmin Li, Guo Shi, et al.Immunotherapy|October 18, 2018
Atezolizumab-induced sarcoid-like granulomatous reaction in a patient with urothelial cell carcinomaMichael A Mitchell, Kevin Hogan, Kayvan AmjadiPageof 188